申请人:Univerza Edvarda Kardelja v Ljubljana
公开号:US05231216A1
公开(公告)日:1993-07-27
There are described novel trans-2-acylaminocyclohexyloxyacyldipeptides of formula I ##STR1## wherein R.sub.1 represents --CO--R.sub.6, --SO.sub.2 --R.sub.7 or ##STR2## R.sub.6 is C.sub.1 -C.sub.18 alkyl or C.sub.1 -C.sub.18 alkoxy, R.sub.7 is C.sub.1 -C.sub.18 alkyl or an optionally substituted phenyl group, Y is .dbd.O, .dbd.S or .dbd.NH; R.sub.2 =R.sub.3 and represent --H or C.sub.1 -C.sub.12 alkyl, R.sub.4 represents --OR.sub.8 or --NHR.sub.9, R.sub.8 is --H, C.sub.1 -C.sub.8 alkyl or benzyl, R.sub.9 is --H, a straight or branched chain C.sub.1 -C.sub.18 alkyl group or benzyl group; R.sub.5 represents --OR.sub.9 or --NHR.sub.9, and novel (1R,2R)- and (1S,2S)-trans-2-acylaminocyclohexyloxyacetyldipeptides of the formulas Ia and Ib ##STR3## wherein R.sub.1 is --CO--R.sub.6, R.sub.6 is C.sub.1 -C.sub.18 alkyl, R.sub.2 is --H, R.sub.3 is --H or C.sub.1 -C.sub.12 alkyl, R.sub.4 is --OR.sub.8 or --NHR.sub.9, R.sub.8 is --H, C.sub.1 -C.sub.8 alkyl or benzyl, R.sub.9 is --H, C.sub.1 -C.sub.18 alkyl or benzyl, R.sub.5 is --OR.sub.9 or --NHR.sub.9 Compounds of formula I, Ia and Ib and the pharmaceutically acceptable alkali salts thereof show immunomodulatory and antitumour activities and can be used in the preparation of medicaments.
本文描述了一种新的转2-酰基氨基环己氧基酰基二肽,其化学式为I,其中R1代表--CO--R6、--SO2--R7或者##STR2## R6为C1-C18烷基或C1-C18烷氧基,R7为C1-C18烷基或可选取代的苯基,Y为.dbd.O、.dbd.S或.dbd.NH;R2和R3代表--H或C1-C12烷基,R4代表--OR8或--NHR9,R8为--H、C1-C8烷基或苄基,R9为--H、直链或支链C1-C18烷基或苄基;R5代表--OR9或--NHR9,以及化学式Ia和Ib的新型(1R,2R)-和(1S,2S)-转2-酰基氨基环己氧基乙酰二肽,其中R1为--CO--R6,R6为C1-C18烷基,R2为--H,R3为--H或C1-C12烷基,R4为--OR8或--NHR9,R8为--H、C1-C8烷基或苄基,R9为--H、C1-C18烷基或苄基,R5为--OR9或--NHR9。化合物I、Ia和Ib及其药用可接受的碱盐具有免疫调节和抗肿瘤活性,并可用于制备药物。